Abstract
Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Current Vascular Pharmacology
Title:Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Volume: 10 Issue: 6
Author(s): Marco De Carlo and Leonardo Misuraca
Affiliation:
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Abstract: Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Export Options
About this article
Cite this article as:
De Carlo Marco and Misuraca Leonardo, Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520855
DOI https://dx.doi.org/10.2174/157016112803520855 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Traditional and Novel Risk Factors of Diabetic Retinopathy and Research Challenges
Current Medicinal Chemistry Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance
Current Diabetes Reviews Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options
Current Vascular Pharmacology Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Novel Mutation of the NOTCH3 Gene in a Chinese Pedigree with CADASIL
CNS & Neurological Disorders - Drug Targets Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design The Impact of Nandrolone Decanoate on the Central Nervous System
Current Neuropharmacology Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Vessel Graft Atherosclerosis in Murine Models
Current Drug Targets Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues
Current Drug Safety